Clinical Trials

Wet (Neovascular) Age-Related Macular Degeneration

ShORe Study

Description: Clinical trial evaluating whether supplementing existing anti-VEGF treatment with a new drug that blocks additional forms of VEGF (a natural chemical which promotes swelling in the retina) will improve treatment response in wet age-related macular degeneration.

Full Title: Phase 3 Multicentre, Double-Masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration

Sponsor: Opthea Limited

Principal Investigator: Scott McClintic, MD

Study Coordinator: Kimberly Flora

Status: Actively Enrolling

Wet (Neovascular) Age-Related Macular Degeneration

DAYLIGHT Study

Description: Phase 3 clinical trial evaluating whether a new, long-acting anti-VEGF medication (KSI-301) will provide better vision outcomes when compared to an existing medication (aflibercept) in the treatment of wet age-related macular degeneration.

Full Title: A Study to Evaluate the Efficacy and Safety of KSI-301 Compared to Aflibercept in Participants with Neovascular (Wet) Age-Related Macular Degeneration

Sponsor: Kodiak Sciences, Inc.

Principal Investigator: Andrew Westfall, MD

Study Coordinator: Kimberly Flora

Status: Enrollment Opening Soon

Wet (Neovascular) Age-Related Macular Degeneration

PULSAR Study

Description: Clinical trial evaluating whether the use of a higher dose of aflibercept, which is already FDA-approved for treatment of wet age-related macular degeneration (AMD), will allow for less frequent eye injections in wet AMD.

Sponsor: Bayer Pharmaceuticals

Principal Investigator: Scott McClintic, MD

Study Coordinator: Dallyce Vetter

Status: In Progress. Closed for New Enrollment

Dry (Atrophic) Age-Related Macular Degeneration

AMD Microbiome Study

Description: Patients with advanced dry AMD provide a blood and stool sample that are analyzed to investigate links between AMD, AMD-associated genes, and changes in the gut bacterial “microbiome.” This study is a collaborative effort between Retina Consultants and OHSU.

Full Title: Association Between Advanced Age-Related Macular Degeneration and Alterations in the Gut Microbiome

On-Site Investigator: Scott McClintic, MD

Principal Investigator: Phoebe Lin, MD, PhD; Oregon Health & Science University

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Dry (Atrophic) Age-Related Macular Degeneration

TELESCOPE Study

Description: Patients with advanced dry AMD provide a saliva sample to screen for AMD-associated genes. If targeted AMD-associated genes are present, subjects may be invited to participate in other trials, including a more extensive natural history study called SCOPE.

Sponsor: Gyroscope Therapeutics

Principal Investigator: Monica Michelotti, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Retinal Vein Occlusion

BEACON Study

Description: Phase 3 clinical trial evaluating whether a new, long-acting anti-VEGF medication (KSI-301) will provide better vision outcomes and allow for less frequent eye injections when compared to an existing medication (aflibercept) in the treatment of macular edema associated with retinal vein occlusion.

Full Title: A Study to Evaluate the Efficacy and Safety of KSI-301 Compared to Aflibercept in Participants with Macular Edema Secondary to Retinal Vein Occlusion (RVO)

Sponsor: Kodiak Sciences, Inc.

Principal Investigator: Andrew Westfall, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

Diabetic Retinopathy

GLIMMER Study

Description: Phase 3 clinical trial evaluating whether a new, long-acting anti-VEGF medication (KSI-301) will provide better vision outcomes and allow for less frequent eye injections when compared to an existing medication (aflibercept) in the treatment of diabetic macular edema.

Full Title: A Study to Evaluate the Efficacy and Safety of KSI-301 Compared to Aflibercept in Participants with Diabetic Macular Edema (DME)

Sponsor: Kodiak Sciences, Inc.

Principal Investigator: Andrew Westfall, MD

Study Coordinator: Marina Sprauer, LPN

Status: Actively Enrolling

 

DRCR (Diabetic Retinopathy Clinical Research network)

Principal Investigator: Scott McClintic, MD

Study Coordinator: Marina Sprauer, LPN

Status: Not currently enrolling

Diabetic Retinopathy

DRCR (Diabetic Retinopathy Clinical Research network): Protocol AF

Description: Study investigating whether an oral medication called fenofibrate (currently FDA-approved for lowering cholesterol) can slow or prevent the worsening of diabetic retinopathy in patients with mild to moderate levels of disease severity.

Full Title: A Randomized Trial of Fenofibrate versus Placebo for Prevention of Diabetic Retinopathy Worsening

Principal Investigator: Scott McClintic, MD

Study Coordinator: Dallyce Vetter

Status: Enrollment Opening Soon

Completed Clinical Trials at Retina Consultants

COPERNICUS Study

A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion.

VIEW 1 Extension Study

An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration.

VIEW 1

A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration